For decades, the molecular switch that drives most pancreatic cancers was ‘undruggable’. No longer. A new drug has now nearly doubled how long patients live.

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease